It is the policy of Temple University School of Medicine, Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all its individually sponsored educational programs. All faculty participating in any Temple University sponsored programs are expected to disclose to the program audience ANY real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. ALL faculty for Diabetes Control in Clinical Practice: A CaseMed Approach have provided disclosure information. Listed below are those faculty who have indicated a relationship with a commercial company. Such disclosure should not be construed as a conflict of interest, but rather as a disclosure of a current or previous financial arrangement. All other faculty have indicated they do not have a financial relationship to disclose. Temple University School of Medicine assures independence and balance of content by resolving current conflicts of interest by reviewing all speaker’s PowerPoint slides prior to their presentation to ensure that the content is based on a structured review for the best scientific evidence at the time of the presentation.
Program Chair
Michael A. Bush, MD
Former Chairman, Division of Endocrinology
Cedars Sinai Medical Center
University of California, Los Angeles;
Practicing Endocrinologist
Medical Associates, Inc.
Los Angeles, California
Disclosure: Amylin Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., NovoNordisk, sanofi-aventis, and Pfizer Labs
Planning Committee
Rodolfo R. Alamia, MD, CDE
Medical Director
Sweet Vida Medical Center
Austin, Texas
Disclosure: Abbott Laboratories, AstraZeneca Pharmaceuticals, Forest Laboratories, Novartis Pharmaceuticals Corp., NovoNordisk, and Pfizer Labs
David L. Bronson, MD, FACP
Chair, Division of Regional Medical Practice
The Cleveland Clinic Foundation
Cleveland, Ohio
Disclosure: Thomson Healthcare
Michael E. Cobble, MD, AAFP, ADA, AHA, ASA, NLA
Board Certified Clinical Lipidologist
Adjunct Faculty
University of Utah School of Medicine;
Medical Director
Canyons Medical Center
Sandy, Utah
Disclosure: Abbott Laboratories, AstraZeneca Pharmaceuticals, Atherotech, CV Terapeutics, Eli Lilly and Co., GlaxoSmithKline, Kos Pharmaceuticals, LCIC, Takeda Pharmaceuticals America, and Wyeth Pharmaceuticals
Luigi F. Meneghini, MD, MBA
Associate Professor of Clinical Medicine
Director of the Eleanor & Joseph Kosow Diabetes Treatment Center
at the Diabetes Research Institute
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: Novo Nordisk, Eli Lilly, Sanofi-Aventis, GSK, Amylin, Pfizer, Merck,
Nipro systems, Medtronic
Susan Potts Sloan, MD
Associate Professor of Medicine
Department of Internal Medicine
James H. Quillen College of Medicine
East Tennessee State University;
President, The Association of American Indian Physicians
Gray, Tennessee
Disclosure: No financial relationships or affiliations to disclose
Ernesto Tamez, Jr, PA
Sweet Vida Medical Center
Austin, Texas
Disclosure: Bristol-Myers Squibb
Penny Tenzer-Iglesias, MD
Vice Chair, Primary Care and Specialty Practices
Department of Family Medicine
Community Health Director, Family Medicine Residency Program
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: No financial relationships or affiliations to disclose
Eugene Wright, Jr, MD
Medical Director & Vice President of the Primary Care Network
Cape Fear Valley Health System
Fayetteville, North Carolina
Disclosure: Amylin Pharmaceuticals, Eli Lilly and Co., and NovoNordisk
